Physiologically-based pharmacokinetic (PBPK) model predicted versus observed effect of Child Pugh mild and moderate hepatic impairment on betrixaban pharmacokinetics

26 August 2018 (15:50 - 16:40)

Organised by:

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Janet Leeds

South San Francisco (United States of America)

5 More presentations in this session

Presentation thumbnail

The influence of sarcopenia on bleeding risk in patients with atrial fibrillation undergoing coronary stenting and subsequent triple antithrombotic therapy

Doctor K. Tsuchida (Niigata, JP)

Abstract Slides

Presentation thumbnail

Interaction of statin therapy to angiotensin ii receptor type 1 blockers in erectile dysfunction patients. effect on endothelial function and aortic stiffness

Doctor N. Ioakeimidis (Athens, GR)

Abstract Slides

Presentation thumbnail

Acute and chronic effect of ticagrelor versus clopidogrel on aortic stiffness

Associate Professor C. Vlachopoulos (Athens, GR)

Abstract Slides

Presentation thumbnail

Cilostazol induces regression of carotid plaque in patients with high cardiovascular risk: CLOVER study. A multicenter, randomized trial.

Professor K. Cho (Busan, KR)

Abstract Slides

Presentation thumbnail

Ticagrelor reduced CD40L level in patient with ST-segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention compared with clopidogrel

Doctor Z. Li (Jinan, CN)

Abstract Slides

Access the full session

Session thumbnail

Optimal surrogate endpoints of drug response

The Event

ESC Congress 2018

26 August 2018 15:50 CET

You may be interested in

Webinar

Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients

Congress Presentation

Antithrombotic therapy in diabetes

Congress Presentation

Contemporary thrombosis management -- state of the state

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources